Noom Unveils Microdose GLP-1 Program at $119 Entry Point

Digital weight loss company Noom has entered the evolving GLP-1 medication landscape with the launch of its Noom Microdose GLP-1Rx Program, offering members personalized microdoses of GLP-1 medications combined with behavioral coaching and clinical support. The program represents a differentiated approach in the increasingly competitive market for GLP-1-based weight management solutions.

The new offering provides doses at 25% or less of typically prescribed maintenance levels, positioning it as an alternative for patients seeking the benefits of GLP-1 medications with potentially reduced side effects. The program starts at $119 for initial enrollment, followed by a monthly fee of $199, which includes prescribed medication, access to the GLP-1 Companion platform, continuous monitoring, clinical adjustments, and refills when medically appropriate.

"I have been microdosing GLP-1s since October. At first, my doctor prescribed it to lower my A1C, but the effects on my health proved far more positive and profound, despite the small dose. That's what makes today's launch personal," Geoff Cook, CEO of Noom, said in a LinkedIn post. "Noom defines a microdose of GLP-1 as a fraction – 25% or less – of the typically prescribed maintenance dose. By that definition, 70% of Noom members receiving microdoses of GLP-1 report no side effects."

The launch comes amid rapid expansion of GLP-1 offerings across digital health platforms. Noom's existing portfolio includes access to standard GLP-1 medications such as Wegovy, Ozempic, Zepbound, Mounjaro, and generic liraglutide, as well as Metformin, all available with prescriptions.

The competitive landscape has seen significant activity and controversy. Hims & Hers partnered with Novo Nordisk in April to offer Wegovy alongside membership services, but the partnership dissolved two months later amid allegations of illegal mass compounding and deceptive marketing practices. "We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients," Hims & Hers CEO Andrew Dedum wrote in a statement posted on X. "We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice."

Other players have developed complementary approaches. MyFitnessPal introduced tools supporting GLP-1 users with nutrition guidance, while Wisp partnered with Nourish to combine weight care programs with insurance-covered nutrition counseling. These varied strategies reflect the market's evolution beyond simple medication access toward comprehensive weight management ecosystems.

Click here for the original news story.